Jemincare and its wholly owned subsidiary Shanghai Jemincare Pharmaceutical have signed an exclusive worldwide license agreement with Roche and Genentech for the development and commercialization of the androgen receptor degrader JMKX-002992.
Staphylococcus aureus is the most common bacterium recovered in orthopedic infections. Exebacase and CF-296 (ContraFect) are known to be anti-staphylococcal lysins with activity against S. aureus.
Halia Therapeutics has presented serine/threonine-protein kinase Nek7 inhibitors reported to be useful for the treatment of cancer, asthma, obesity, type 2 diabetes, hepatitis, peritonitis, neurodegeneration and psoriasis, among others.
The development of cancer after p53 inactivation is determined by a series of genomic changes that occur in four steps. The loss of heterozygosity of TP53 (the gene encoding p53 in humans, named Trp53 in mice) is followed by an accumulation of deletions, genome doubling, and the emergence of gains and amplifications.
HiberCell has described eukaryotic translation initiation factor 2-alpha kinase 4 (GCN2) inhibitors reported to be useful for the treatment of cancer, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis and spinocerebellar ataxia.
Blue Water Vaccines (BWV) will attempt to present monkeypox antigens within its norovirus shell and protrusion (S&P) virus-like particle (VLP) platform to develop a novel monkeypox vaccine.
There is a need of better markers that reflect key mechanisms involved in diabetic kidney disease (DKD). In a new study, investigators have identified increased concentrations of neuroblastoma suppressor of tumorigenicity 1 (NBL1) as a strong and independent predictor of progression to end-stage kidney disease (ESKD) in patients with diabetes.
RSS